A New Approach to

Metagenomics

We’ve developed and patented DNA sequencing technology that is the preferred method of the NIH Human Microbiome Project.

MultiTag™ Sequencing

MultiTag™ Sequencing offers a new approach to metagenomics by enabling amplification bias free sample barcoding for next-generation sequencing-based analyses.

Microbial DNA Sequencing

Metagenomics diagnostics requires specialized patented microbial DNA sequencing methods and bioinformatics that have been developed and proven over the past 10 years. One patented technology uses high-throughput next-generation sequencing for clinical research, diagnosis, prognostication, and/or monitoring of disease progression in inflammatory bowel disease (IBD), polymicrobial, and immunological diseases. Our patented MultiTag™ Sequencing platform provides a means of applying high-throughput DNA sequencing methods such as pyrosequencing to metagenomics research, clinical research, and diagnostic testing by adding unique barcodes for identifying a hundred or more individual patient samples in a single high-throughput DNA sequencing run. This technology enables the use of DNA sequencing with advanced bioinformatics and comparative statistical analysis to economically perform clinical trials and diagnostic testing of individual patients.

Metabiomics Safe Harbor Statement: This press website contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the potential results and future outcomes our clinical research and business plan; ability to discover biomarkers and diagnostic tests; our beliefs regarding the need for and value of molecular diagnostics; and the focus and attributes of the company’s product pipeline, including the ability of the company’s tests to impact clinical practice. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the results of clinical and developmental studies; the applicability of clinical study results to actual outcomes; our ability to develop and commercialize new tests and the timing thereof; unanticipated costs or delays in research and development efforts; the applicability of initial next generation sequencing studies to future results; the risk that we may not obtain or maintain reimbursement for diagnostic tests we may develop, both domestically and abroad; our ability to compete against third parties; the risks and uncertainties associated with the regulation of our tests by the FDA and other agencies abroad; and the other risks set forth in the company’s business plans and presentations. These forward- looking statements speak only as of the date hereof. Metabiomics disclaims any obligation to update these forward-looking statements.

Contact Us

If you are interested in learning more about how Metabiomics is working to change the colon cancer screening paradigm, we would love to hear from you.